Unbelievably, measles is a problem in the U.S. again.
At the moment, the U.S. has confirmed 695 measles cases this year. That’s the highest since the country eliminated in 2000, according to the U.S. Centers for Disease Control and Prevention.
In fact, according to the U.S. CDC:
“This current outbreak is deeply troubling and I call upon all healthcare providers to assure patients about the efficacy and safety of the measles vaccine, said CDC Director Robert Redfield. And, I encourage all Americans to adhere to CDC vaccine guidelines in order to protect themselves, their families, and their communities from measles and other vaccine preventable diseases.”
“The high number of cases in 2019 is primarily the result of a few large outbreaks – one in Washington State and two large outbreaks in New York that started in late 2018. The outbreaks in New York City and New York State are among the largest and longest lasting since measles elimination in 2000. The longer these outbreaks continue, the greater the chance measles will again get a sustained foothold in the United States.”
If not treated in children, one out of every 20 can get pneumonia, the most common cause of death from measles. About one child out of 1,000 can develop encephalitis (swelling of the brain, which can lead to convulsions and even leave a child deaf).
In short, this isn’t something you’d even wish on your worst enemy.
"We are fighting a disease now in 2019 that should have been off the table in the 1960s with the development of the vaccine,” said Dr. Amesh Adalja, an infectious disease expert with the Johns Hopkins Center for Health Security, as quoted by Reuters. "It should be viewed as an embarrassment that so many Americans have turned away from vaccines that we are having a record year for measles."
One of the top stocks to watch with news of the outbreak is Merck (MRK)., which provides the MMR (mumps, measles, rubella) vaccine. At the moment, the company is the sole provider of the shot, and has “taken steps to increase U.S. supply.”
What’s concerning is that even adults that were vaccinated years ago, may need a new dose based on when they received the shot, and their exposure to risk.
It’s an unfortunate issue that should no longer be a problem.
After being asked by investors about the situation, and potential stocks to watch, we’re providing this information. To all our readers, we wish you good health.